Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

153 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Safety considerations with omega-3 fatty acid therapy.
Bays HE. Bays HE. Am J Cardiol. 2007 Mar 19;99(6A):35C-43C. doi: 10.1016/j.amjcard.2006.11.020. Epub 2006 Nov 28. Am J Cardiol. 2007. PMID: 17368277 Review.
Fish oil (omega-3 fatty acids) in treatment of hypertriglyceridemia. A practical approach for the primary care physician.
Bays H, Lansing AM. Bays H, et al. J Ky Med Assoc. 1994 Mar;92(3):105-8. J Ky Med Assoc. 1994. PMID: 8035110
Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group.
Stein EA, Davidson MH, Dobs AS, Schrott H, Dujovne CA, Bays H, Weiss SR, Melino MR, Stepanavage ME, Mitchel YB. Stein EA, et al. Among authors: bays h. Am J Cardiol. 1998 Aug 1;82(3):311-6. doi: 10.1016/s0002-9149(98)00421-4. Am J Cardiol. 1998. PMID: 9708659 Clinical Trial.
Drug interactions of lipid-altering drugs.
Bays HE, Dujovne CA. Bays HE, et al. Drug Saf. 1998 Nov;19(5):355-71. doi: 10.2165/00002018-199819050-00003. Drug Saf. 1998. PMID: 9825949 Review.
Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia.
Stein E, Plotkin D, Bays H, Davidson M, Dujovne C, Korenman S, Stepanavage M, Mercuri M. Stein E, et al. Among authors: bays h. Am J Cardiol. 2000 Aug 15;86(4):406-11. doi: 10.1016/s0002-9149(00)00955-3. Am J Cardiol. 2000. PMID: 10946033 Clinical Trial.
Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients.
Bays HE, Stein EA, Shah AK, Maccubbin DL, Mitchel YB, Mercuri M. Bays HE, et al. Am J Cardiol. 2002 Nov 1;90(9):942-6. doi: 10.1016/s0002-9149(02)02658-9. Am J Cardiol. 2002. PMID: 12398959 Clinical Trial.
Existing and investigational combination drug therapy for high-density lipoprotein cholesterol.
Bays H. Bays H. Am J Cardiol. 2002 Nov 20;90(10B):30K-43K. doi: 10.1016/s0002-9149(02)02971-5. Am J Cardiol. 2002. PMID: 12467938
Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia.
Isaacsohn J, Hunninghake D, Schrott H, Dujovne CA, Knopp R, Weiss SR, Bays H, Crouse JR 3rd, Davidson MH, Keilson LM, McKenney J, Korenman SG, Dobs AS, Stein E, Krauss RM, Maccubbin D, Cho M, Plotkin DJ, Mitchel YB. Isaacsohn J, et al. Among authors: bays h. Clin Cardiol. 2003 Jan;26(1):18-24. doi: 10.1002/clc.4960260105. Clin Cardiol. 2003. PMID: 12539808 Free PMC article. Clinical Trial.
Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
Bays HE, Dujovne CA, McGovern ME, White TE, Kashyap ML, Hutcheson AG, Crouse JR; ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation. Bays HE, et al. Am J Cardiol. 2003 Mar 15;91(6):667-72. doi: 10.1016/s0002-9149(03)00007-9. Am J Cardiol. 2003. PMID: 12633795 Clinical Trial.
Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol.
Bays HE, McKenney JM, Dujovne CA, Schrott HG, Zema MJ, Nyberg J, MacDougall DE; Gemcabene Study Group. Bays HE, et al. Am J Cardiol. 2003 Sep 1;92(5):538-43. doi: 10.1016/s0002-9149(03)00721-5. Am J Cardiol. 2003. PMID: 12943873 Clinical Trial.
153 results
Jump to page
Feedback